Italians have no doubts when asked what characteristics the health care of the future must have, which cannot and must not let the lesson of Covid escape. There is also no doubt about who should be the protagonist: the citizens themselves the doctor is increasingly informed, responsible and involved as the highest guarantor of the protection of health and innovators, that is to say researchers and businesses. This is what emerges from the new Censis report published on the occasion of the first edition of “The Italian Health Day” by Janssen Italia, a research carried out within the framework of the project “Building sites for the health of the future”, launched in 2021 with the aim of identifying the orientations for the development of post-Covid Health.
The key word of the Censis Report, which expresses ideas, expectations and desires shared both at social and institutional level by citizens, is “RInnovAzione” for 2022. It is a neologism composed of Research, Innovation, Action and Renew , words that recall decisive dynamics for building a Health that maximizes the Health value. From the central role of innovators, to change through the active participation of healthcare stakeholders, to the historic opportunity for a historic shift in healthcare towards personalization, better health outcomes for people and sustainability economic.
“Italians, grateful to health care for what they have done in emergencies, now look to them projected into the future” – says Massimiliano Valerii, CEO of Censis. “Personalized care, superior outcomes, improved quality of life and economic sustainability are the variables of a difficult equation which, if the role of innovators is properly exploited, from researchers to pharmaceutical companies so appreciated by citizens, will certainly be resolved. Unsurprisingly, the majority of Italians are convinced that in the years to come, thanks also to the lessons of this two-year period, the health service is destined to improve. The many challenges ahead, starting with the need to respond to chronic diseases, acute situations and emergencies, certainly require more resources, more staff, more beds and more services, but to ensure that everything is sustainable in the long term term, it is crucial to give a strong push towards “innovation and research, from medicines to services and the intelligent use of data, so as to maximize the value for health” – says the director of Censis.
Personalization of care
According to Italians, the health of tomorrow will have to be increasingly patient-centric and tailor-made: 94.3% hope for greater personalization of care, 92.9% expecting care pathways, from home to territory to hospitals, are adapted to the personal needs of the patient. “Putting the patient at the center means reversing the perspective and thinking about health services that reach citizens, are close and widespread in the region, and use digitization as a tool to respond quickly and in a personalized way to their needs” – says Anna Lisa Mandorino, general secretary of Cittadinanzattiva. “At the same time, especially for the prevention and management of chronic diseases, there must be a very close network of connections between professionals, starting with general practitioners, pediatricians who are free to choose and operators present in new community houses: in this way we can win the challenge of really strengthening local assistance, as foreseen by the PNRR “- he says.
The centrality of the doctor and the proximity
The personalization of care, the centrality of the doctor, proximity as territorial assistance, trust in drug companies and in the drugs themselves, the key role of innovation, which is decisive for the improvement of care, medical pathways assistance and defenses in the face of new emergencies. The Censis report shows that more than 9 out of 10 people trust scientific researchers (90.9%) and as many believe that public health spending represents an investment and not a cost (93.7%).
Janssen Italia’s commitment
“We are happy to be able to continue the debate on the health of the future with Censis” – said Massimo Scaccabarozzi, President of Janssen Italy and Head of External Affairs of Johnson & Johnson Italy. “The report presented clearly shows what Italians expect from post-Covid health care and we can only agree with what they have expressed, starting with the demand for greater public-private collaboration. to bring innovation to patients ever faster. . We are also happy to see that Italians place great trust in pharmaceutical companies and that their role is recognized in the field of innovation, both in emergency situations and in ordinary situations. Clinical research is, in fact, the cornerstone of our business, just think that there are 14 new molecules that Janssen is working on, especially in the oncology and immunology fields, for them to be available to patients,” he concludes.